1. Data on file. Eagle Pharmaceuticals, Inc.
  2. Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg. 2014;118(2):381-387.
  3. Brandom BW, Kang A, Sivak EL, Young MC. Update on dantrolene in the treatment of anesthetic induced malignant hyperthermia. SOJ Anesthesiol Pain Manag. 2015;2(2):1-6.
  4. Schütte JK, Becker S, Burmester S, et al. Comparison of the therapeutic effectiveness of a dantrolene sodium solution and a novel nanocrystalline suspension of dantrolene sodium in malignant hyperthermia normal and susceptible pigs. Eur J Anaesthesiol. 2011;28(4):256-264.
  5. Dantrium Intravenous [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies, Inc.; 2014.
  6. Revonto [prescribing information]. Louisville, KY: US WorldMeds, LLC; 2014.
  7. RYANODEX [prescribing information]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2017.
  8. Managing an MH crisis. Malignant Hyperthermia Association of the United States website. Accessed March 24, 2017.
  9. Revonto Dosage and Administration. Revonto website. Accessed June 4, 2018.
  10. Rosenberg H, Sambuughin N, Riazi S, Dirksen R. Malignant Hyperthermia Susceptibility. 2003 [updated 2013]. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.
  11. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.
  12. Nelson P, Litman RS. Malignant hyperthermia in children: an analysis of the North American malignant hyperthermia registry. Anesth Analg. 2014;118(2):369-374.
  13. Rosenberg H. Current state of malignant hyperthermia and the use of Dantrium IV as treatment. Anesthesiology News. 2010:20-21.
  14. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg. 2010;110(2):498-507.
  15. Brandom BW. Cases from the North American MH Registry/MHAUS [1992 through 2012].
  16. Post acute phase. Malignant Hyperthermia Association of the United States website. Accessed March 24, 2017.
  17. Pollock NA, Machon RG, Rosenberg H. Early development, identification of mode of action, and use of dantrolene sodium. The role of Keith Ellis, Ph.D. Anesthesiology. 2017;126(5):774-779.
  18. FAQs: Stocking an MH cart. Malignant Hyperthermia Association of the United States website. Accessed May 5, 2017.

Indication and Important Safety Information